Cyclana Bio

Cyclana Bio is a Babraham, Cambridge-based biotechnology startup that develops physiologically accurate human tissue models to advance women's health research and therapeutic development. The company specifically focuses on endometriosis by engineering in vitro models that replicate human endometrial tissue, integrating multi-scale biological data such as epigenetics, extracellular matrix biology, and cell signaling. These advanced tissue-level models allow pharmaceutical companies to test potential therapies in conditions that accurately mimic the complex disease environment, effectively addressing the critical limitations of traditional cell-level studies. Operating as an early-stage venture focused on closing the gender health gap through scientific discovery, the organization recently secured £5 million in a pre-seed funding round co-led by NFX, with additional participation from Eka Ventures, Wilbe, and Cocoa VC. Cyclana Bio was founded in 2024 by Dr. Léa Wenger and Prof. Kevin Chalut.